Extended anticoagulation with apixaban reduces hospitalisations in patients with venous thromboembolism

Summary

Treatment with apixaban versus placebo for 12 months significantly reduced symptomatic recurrent venous thromboembolism (VTE) or all-cause death without increasing the rate of major bleeding in the AMPLIFY-EXT trial. This analysis examined the effects of apixaban versus placebo on the rate of all-cause hospitalisations, time to first hospitalisation, and predictors of first hospitalisation in patients with VTE enrolled in AMPLIFY-EXT. Treatment with apixaban 2.5 mg and 5 mg twice daily significantly reduced the rate of all-cause hospitalisations versus placebo (hazard ratio [95 % confidence interval], 0.64 [0.43, 0.95]; p=0.026 and 0.54 [0.36, 0.82]; p=0.004, respectively). Apixaban prolonged mean time to first hospitalisation versus placebo by 43 and 49 days for the 2.5-mg and 5-mg twice-daily groups, respectively. Median length of hospital stay during the first hospitalisation was longer for placebo than for apixaban 2.5 mg or 5 mg twice daily (7.0, 5.0, and 4.5 days, respectively). Treatment with apixaban was a significant predictor of lower rates of hospitalisations versus placebo, and severe/moderate renal impairment was a significant predictor of an increased rate. This study supports extended use of apixaban for reducing all-cause hospitalisations and extending time to first hospitalisation in patients with VTE enrolled in AMPLIFY-EXT (www.clinical trials.gov registration: #NCT00633893).

Keywords

Apixaban - hospitalisation - venous thromboembolism - extended anticoagulation

• References

• 1 Goldhaber SZ. Preventing pulmonary embolism and deep vein thrombosis: a ‘call to action’ for vascular medicine specialists. J Thromb Haemost 2007; 05: 1607-1609.
• 2 Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med 2012; 09: e1001275.
• 3 Huerta C, Johansson S, Wallander MA. et al. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med 2007; 167: 935-943.
• 4 Pannucci CJ, Shanks A, Moote MJ. et al. Identifying patients at high risk for venous thromboembolism requiring treatment after outpatient surgery. Ann Surg 2012; 255: 1093-1099.
• 5 Silverstein MD, Heit JA, Mohr DN. et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158: 585-593.
• 6 Kearon C, Akl EA, Comerota AJ. et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e419S-e94S.
• 7 Torbicki A, Perrier A, Konstantinides S. et al. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008; 29: 2276-2315.
• 8 Coumadin® [warfarin] prescribing information.. Bristol-Myers Squibb Pharma Company: Princeton, NJ. Available at: http://packageinserts.bms.com/pipi_coumadin.pdf. 2011 Accessed July 15, 2015.
• 9 Frost C, Nepal S, Wang J. et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol 2013; 76: 776-786.
• 10 Frost C, Yu Z, Nepal S. et al. Apixaban, a direct factor Xa inhibitor: single-dose pharmacokinetics and pharmacodynamics of an intravenous formulation. J Clin Pharmacol 2008; 48: 1132. Abstract 142.
• 11 Agnelli G, Buller HR, Cohen A. et al. AMPLIFY Investigators.. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369: 799-808.
• 12 Liu X, Johnson M, Mardekian J. et al. Apixaban reduces hospitalizations in patients with venous thromboembolism: an analysis of the AMPLIFY trial. Oral presentation at: ACC 2014; March 29–31, 2014; Washington, DC.
• 13 Agnelli G, Buller HR, Cohen A. et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368: 699-708.
• 14 Claflin AB, Mitchell CR, Liu X. et al. Economic burden of venous thromboembolism across patient populations: a literature review. Value Health 2013; 16: A519. Abstract PCV44.
• 15 Khorana AA, Dalal MR, Lin J. et al. Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States. Clinicoecon Outcomes Res 2013; 05: 101-108.
• 16 van den Belt AG, Bossuyt PM, Prins MH. et al. Replacing inpatient care by out-patient care in the treatment of deep venous thrombosis–an economic evaluation. TASMAN Study Group. Thromb Haemost 1998; 79: 259-263.
• 17 Spyropoulos AC, Lin J. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J Manag Care Pharm 2007; 13: 475-486.
• 18 Raghavan N, Frost CE, Yu Z. et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 2009; 37: 74-81.
• 19 Eliquis® [apixaban tablets].. Prescribing information. Bristol-Myers Squibb Company: Princeton, NJ. Available at: http://packageinserts.bms.com/pi/pi_eliquis.pdf. Accessed March 20, 2014.
• 20 Chang M, Yu Z, Shenker A. et al. Apixaban pharmacokinetics and pharmacodynamics in subjects with renal impairment. Poster presented at ACCP 2012. October 21–24, 2012; Hollywood, FL.
• 21 Hohnloser SH, Hijazi Z, Thomas L. et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012; 33: 2821-2830.